Savara Pharmaceuticals Raises $16M

Austin-based Savara Pharmaceuticals, which is developing inhaled antibiotics to treat MRSA infection in cystic fibrosis patients, has raised $16M more in a Series B funding round. The round came from the Tech Coast Angels, Rady Venture Fund, Keiretsu Forum, the Central Texas Angel Network (CTAN) and the North Texas Angel Network (NTAN). Savara is developing an inhaled antibiotic for treatment of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF) patients. More information »